Granules India Limited (NSE: GRANULES) is a pharmaceutical manufacturing company based in Hyderabad, India. The company was founded in 1984 and has grown to become a leading producer of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, and other healthcare products.
Revenue from Operations was ₹1,146 Cr, up 15% year on year, primarily due to higher Paracetamol API sales in the US. The revenue share from the United States increased to 49.4% in Q3 FY23, up from 43.1% the previous year. Active pharmaceutical ingredients (API), pharmaceutical formulation intermediates (PFI), and finished dosages each contribute 35.8%, 18.6%, and 45.6% of revenue from operations. The Consolidated Net Profit was ₹124.32 crore, up from ₹100.88 crore in the same quarter last year. This quarter’s earnings per share was ₹5.10.
While operating cash flow is quite healthy at ₹161 Cr, free cash flow has been impacted at (₹32.5) Cr due to additional deployments of ₹50 Cr in our new expansion plan with green initiatives in Kakinada and ₹42.5 Cr for land acquisition in Vishakhapatnam. ROCE increased to 25.6% from 21.2% year on year.